Cure8 research brief
CVID-related enteropathy can resemble celiac disease or IBD, carries high morbidity and mortality, and often does not respond to standard immunoglobulin therapy — patients and clinicians need awareness of its distinct mechanisms and limited evidence for treatments.
Clinicians (gastroenterologists, immunologists), researchers studying immune-mediated enteropathies or IBD-like conditions, and adult patients with CVID experiencing chronic enteropathy or refractory GI symptoms.
This abstract reviews enteropathy in common variable immunodeficiency (CVID-E), summarizing pathology (villous atrophy, absent mucosal plasma cells, CD8+ T cell infiltration), proposed pathogenic mechanisms (IgA deficiency, interferon-driven CD8 cytotoxicity, chronic norovirus), registry findings on comorbidity and outcomes, and current/experimental treatments including corticosteroids, TNF-α blockers, thiopurines, JAK inhibitors, and abatacept.
It notes immunoglobulin replacement does not improve enteropathy and calls for randomized trials and precision therapies.
This record is an abstract summarizing current understanding and perspectives, not a full randomized trial or guideline. Recommendations are based on limited evidence and observational/registry data; the abstract emphasizes need for controlled trials.
Some treatments noted (JAK inhibitors, abatacept) are proposed based on mechanistic rationale or small cohorts rather than large RCT results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
